Elan could receive drug royalty payments
Johnson & Johnson’s injection treatment for patients with schizophrenia — Paliperidone Palmitate — was lodged as a new drug application to the Food and Drug Administration (FDA) in the US last October.
The FDA is expected to give the green light for the commercialisation of the treatment later this year.